Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 5, 2007

PolyMedix Lands SBIR Grant for Anticoagulant Antagonists

  • PolyMedix received a phase 1 SBIR grant from the National Heart, Lung, and Blood Institute. The six-month, $100,000 backing will support the development of biomimetic compounds as anticoagulant antagonists.

    PolyMedix says that it the funding will go toward the company’s continued efforts to develop new compounds as antagonists to heparin and low molecular weight heparin. It calls these compounds heptagonists.

    PolyMedix hopes to file an IND application during the first quarter of 2008. Upon successful completion of the phase 1 portion of the work, PolyMedix plans to submit a request for additional funding.

    This award reportedly is the fifth SBIR grant awarded to the company. Previous grants totaled $3.5 million and were given in support of antibiotic development.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »